



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kristian Berg et al.
Title: METHOD OF VACCINATION
Docket No.: 697.013US1
Filed: March 10, 2000
Examiner: Unknown

Serial No.: 09/524,454
Due Date: N/A
Group Art Unit: Unknown

Assistant Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- X A return postcard.
- X Communication Regarding Filing of Priority Document in Accordance with 35 U.S.C. 119 (1 Page).
- X Certified Copy of Great Britain Application No. 9905911.5 (18 pgs.).

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described above, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 6 day of April, 2000.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Ann M. McCrackin
Atty: Ann M. McCrackin
Reg. No. 42,858

Customer Number 21186

(GENERAL)

#6

S/N 09/524,454

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kristian Berg et al.

Serial No.: 09/524,454

Filed: March 10, 2000

Title: METHOD OF VACCINATION



Examiner: Unknown

Group Art Unit: Unknown

Docket: 697.013US1

**COMMUNICATION REGARDING FILING OF PRIORITY
DOCUMENT IN ACCORDANCE WITH 35 U.S.C. 119**Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir or Madam:

In accordance with the requirements for claiming right of priority under 35 U.S.C. 119, enclosed for filing in connection with the above-identified application is a certified copy of Applicants' prior application, Great Britain Application No. 9905911.5, filed on March 15, 1999.

Respectfully submitted,

KRISTIAN BERG ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 349-9592Date April 6, 2000By Ann M. McCrackinAnn M. McCrackin
Reg. No. 42,858

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231 on April 6, 2000.

ANN MCCRACKIN
NameAnn M. McCrackin
Signature



The
**Patent
Office**



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

22nd March 2000





The
Patent
Office

1/77

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1.	Your reference	27.69920		
2.	Patent application number (The Patent Office will fill in this part)	9905911.5		
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	PhotoCure AS Montebello P.O. Box 55 N-0310 Oslo Norway		
	Patents ADP number (if you know it)			
	If the applicant is a corporate body, give country/state of incorporation	Norway	7132889001	
4.	Title of the invention	Method		
5.	Name of your agent (if you have one)	Frank B. Dehn & Co.		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL		
	Patents ADP number (if you know it)	166001		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	21
Claim(s)	0
Abstract	0
Drawing(s)	5 d s

10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

11.

I/We request the grant of a patent on the basis of this application.

Hanna Dzieglewska
Signature

Date 15 March 1999

12. Name and daytime telephone number of person to contact in the United Kingdom

Hanna Dzieglewska
0171 206 0600

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

69920.604

METHOD

5 The present invention relates to a method of
vaccination which involves using photodynamic treatment
(PDT) to introduce vaccine components into cells to
achieve antigen presentation, and to vaccine
compositions useful in such a method.

10 The majority of molecules do not readily penetrate
cell membranes. Methods for introducing molecules into
the cytosol of living cells are useful tools for
manipulating and studying biological processes. Among
the most commonly used methods today are microinjection,
15 red blood cell ghost-mediated fusion and liposome
fusion, osmotic lysis of pinosomes, scrape loading,
electroporation, calcium phosphate and virus-mediated
transfection. These techniques are useful for
investigating cells in culture, although in many cases
they may be impractical, time consuming, inefficient or
20 they may induce significant cell death. Thus such
techniques are not optimal for use in biological or
medical research, or in therapies, where it is required
that cells should remain viable and/or functional.

25 It is well known that porphyrins and many other
photosensitizing compounds may induce cytotoxic effects
on cells and tissues. These effects are based upon the
fact that upon exposure to light the photosensitizing
compound may become toxic or may release toxic
substances such as singlet O₂ or other oxidising radicals
30 which are damaging to cellular material or biomolecules,
including the membranes of cells and cell structures,
and such cellular or membrane damage may eventually kill
the cells. These effects have been utilised in the
treatment of various abnormalities or disorders,
35 including especially neoplastic diseases. The treatment
is named photodynamic therapy (PDT) and involves the
administration of photosensitizing

(photochemotherapeutic) agents to the affected area of the body, followed by exposure to photoactivating light in order to activate the photosensitizing agents and convert them into cytotoxic form, whereby the affected cells are killed or their proliferative potential diminished. Photosensitizing agents are known which will localise preferentially or selectively to the desired target site e.g. to a tumour or other lesion.

A range of photosensitizing agents are known, including notably the psoralens, the porphyrins, the chlorins and the phthalocyanins. Such drugs become toxic when exposed to light.

Photosensitizing drugs may exert their effects by a variety of mechanisms, directly or indirectly. Thus for example, certain photosensitisers become directly toxic when activated by light, whereas others act to generate toxic species, e.g. oxidising agents such as singlet oxygen or other oxygen-derived free radicals, which are extremely destructive to cellular material and biomolecules such as lipids, proteins and nucleic acids.

Porphyrin photosensitisers act indirectly by generation of toxic oxygen species, and are regarded as particularly favourable candidates for PDT. Porphyrins are naturally occurring precursors in the synthesis of heme. In particular, heme is produced when iron (Fe^{3+}) is incorporated in protoporphyrin IX (Pp) by the action of the enzyme ferrochelatase. Pp is an extremely potent photosensitizer, whereas heme has no photosensitizing effect. A variety of porphyrin-based or porphyrin-related photosensitisers are known in the art and described in the literature.

The cytotoxic effect is mediated mainly through the formation of singlet oxygen. This reactive intermediate has a very short lifetime in cells ($<0.04 \mu\text{s}$). Thus, the primary cytotoxic effect of PDT is executed during light exposure and very close to the sites of formation of $^1\text{O}_2$. $^1\text{O}_2$ reacts with and oxidizes proteins (histidine,

tryptophan, methionine, cysteine, tyrosine), DNA (guanine), unsaturated fatty acids and cholesterol. One of the advantages of PDT is that tissues unexposed to light may be left unaffected ie. that a selective PDT effect may be obtained. There is extensive documentation regarding use of PDT to destroy unwanted cell populations, for example neoplastic cells. The patent literature describes a number of photodynamic compounds, alone or conjugated with targeting agents, e.g. immunoglobulins directed to neoplastic cell receptor determinants, making the complex more cell specific. Certain photochemical compounds, such as hematoporphyrin derivatives, have furthermore an inherent ability to localise in malignant cells. Such methods and compounds, are described in the Norwegian patent NO 173319, in Norwegian patent applications Nos. 90 0731, 176 645, 176 947, 180 742, 176 786, 301 981, 30 0499 and 89 1491.

In WO93/14142 a drug delivery system is described which comprises an anti-cancer agent and a photoactivatable agent (ie. a photosensitizer) attached to copolymeric carriers. Upon administration this complex enters the cell interior by pinocytosis or phagocytosis and locates inside the endosomes and lysosomes. In the lysosomes, the bond between the anti-neoplastic agent and the polymer is hydrolysed and the former can diffuse passively through the lysosome membrane into the cytosol. The utility of this method is thus limited to small molecular compounds which are able to diffuse across the lysosome membranes. After allowing a time lag for diffusion, a light source of appropriate wavelength and energy is applied to activate the photo-activatable compound. The combined effect of the anti-cancer agent and photoactivatable agent destroy the cell.

Such PDT methods as described above are thus directed to the destruction of cell structures leading

to cell death.

WO 96/07432, on the other hand, is concerned with methods which use the photodynamic effect as a mechanism for introducing otherwise membrane-impermeable molecules into the cytosol of a cell in a manner which does not result in widespread cell destruction or cell death. In this method, the molecule is co-internalised (more particularly "endocytosed") into an intracellular vesicle in the cell (e.g. a lysosome or endosome) together with a photosensitizing agent. The cell is then exposed to photoactivating light which "activates" the photosensitizer, which in turn causes the vesicle membrane to disrupt or rupture, releasing the vesicle contents, including the molecule, into the cell interior ie. the cytosol. It was found that in such a method the functionality or the viability of the majority of the cells was not deleteriously affected. Thus, the utility of such a method, termed "photochemical internalisation" was proposed for transporting a variety of different molecules, including therapeutic agents, into the cytosol ie. into the interior of a cell.

We have now found that such a method can advantageously be used, not only to transfer molecules in the interior of a cell, but also to present or express them on a cell surface. Thus, following transport and release of a molecule into the cell cytosol, it may be transported to the surface of the cell where it may be presented on the outside of the cell ie. on the cell surface. Such a method has particular utility in the field of vaccination, where vaccine components ie. antigens or immunogens, may be introduced to a cell for presentation on the surface of that cell, in order to induce, facilitate or augment an immune response.

At its most general, the present invention thus provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting

cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell.

5 Such antigenic presentation may advantageously result in the stimulation of an immune response, and consequently the invention finds particular utility as a method of vaccination.

10 More particularly, this aspect of the invention provides a method of expressing an antigenic molecule on the surface of a cell, said method comprising:

15 contacting said cell with said antigenic molecule and with a photosensitizing agent, wherein said molecule and said agent are each taken up into an intracellular membrane-restricted compartment of said cell; and

20 irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, such that the membrane of said intracellular compartment is disrupted, releasing said molecule into the cytosol of the cell, without killing the cell,

 wherein, said released antigenic molecule, or a part thereof, is subsequently presented on the surface of said cell.

25 Alternatively viewed, this aspect of the invention also provides a composition for use in expressing an antigenic molecule on the surface of a cell, said composition comprising an antigenic molecule and a photosensitizing agent.

30 In a further aspect, the invention also provides the use of an antigenic molecule and a photosensitizing agent in the preparation of a composition for use in expressing said antigenic molecule or a part thereof on the surface of a cell.

35 A still further aspect of the invention provides a product comprising an antigenic molecule and a photosensitizing agent as a combined preparation for simultaneous, separate or sequential use in expressing

said antigenic molecule or a part thereof on the surface of a cell.

5 A yet further aspect of the invention provides a kit for use in expressing an antigenic molecule or a part thereof on the surface of a cell, said kit comprising

a first container containing said antigenic molecule; and

10 a second container containing a photosensitizing agent.

In the invention, the antigenic molecule may be any molecule capable of stimulating an immune response, when presented to the immune system in an appropriate manner. Advantageously, therefore the antigenic molecule will be
15 a vaccine antigen or vaccine component.

Many such antigens or antigenic vaccine components are known in the art and include all manner of bacterial or viral antigens or indeed antigens or antigenic components of any pathogenic species including protozoa
20 or higher organisms. Whilst traditionally the antigenic components of vaccines have comprised whole organisms (whether live, dead or attenuated) ie. whole cell vaccines, in addition sub-unit vaccines, ie. vaccines based on particular antigenic components of organisms
25 e.g. proteins or peptides, or even carbohydrates, have been widely investigated and reported in the literature. Any such "sub-unit"-based vaccine component may be used as the antigenic molecule of the present invention. However, the invention finds particular utility in the
30 field of peptide vaccines. Thus, a preferred antigenic molecule according to the invention is a peptide (which is defined herein to include peptides of both shorter and longer lengths ie. peptides, oligopeptides or polypeptides, and also protein molecules or fragments thereof e.g. peptides of 5-500 e.g. 10 to 250 amino
35 acids).

A vast number of peptide vaccine candidates have

been proposed in the literature, for example in the treatment of viral diseases and infections such as AIDS/HIV infection or influenza, canine parvovirus, bovine leukaemia virus, hepatitis, etc. (see e.g. Phanuphak et al., Asian Pac. J. Allergy. Immunol. 1997, 15(1), 41-8; Naruse, Hokkaido Igaku Zasshi 1994, 69(4), 811-20; Casal et al., J. Virol., 1995, 69(11), 7274-7; Belyakov et al., Proc. Natl. Acad. Sci. USA, 1998, 95(4), 1709-14; Naruse et al., Proc. Natl. Sci. USA, 1994 91(20), 9588-92; Kabeya et al., Vaccine 1996, 14(12), 1118-22; Itoh et al., Proc. Natl. Acad. Sci. USA, 1986, 83(23) 9174-8. Similarly bacterial peptides may be used, as indeed may peptide antigens derived from other organisms or species.

In addition to antigens derived from pathogenic organisms, peptides have also been proposed for use as vaccines against cancer or other diseases such as multiple sclerosis. For example, mutant oncogene peptides hold great promise as cancer vaccines acting as antigens in the simulation of cytotoxic T-lymphocytes. (Schirrmacher, Journal of Cancer Research and Clinical Oncology 1995, 121, 443-451; Curtis Cancer Chemotherapy and Biological Response Modifiers, 1997, 17, 316-327). A synthetic peptide vaccine has also been evaluated for the treatment of metastatic melanoma (Rosenberg et al., Nat. Med. 1998, 4(3), 321-7). A T-cell receptor peptide vaccine for the treatment of multiple sclerosis is described in Wilson et al., J. Neuroimmunol. 1997, 76(1-2), 15-28. Any such peptide vaccine component may be used as the antigenic molecule of the invention, as indeed may any of the peptides described or proposed as peptide vaccines in the literature. The peptide may thus be synthetic or isolated or otherwise derived from an organism.

The cell which is subjected to the methods, uses etc. of the invention may be any cell which is capable of expressing, or presenting on its surface a molecule

which is administered into its cytosol.

Since the primary utility of the invention resides in antigen-presentation or vaccination, the cell is conveniently an immune effector cell ie. a cell involved in the immune response. However, other cells may also present antigen to the immune system and these are also covered. The cells according to the present invention are thus advantageously antigen-presenting cells. The antigen-presenting cell may be involved in any aspect or "arm" of the immune response, including both humoral and cell-mediated immunity, for example the stimulation of antibody production, or the stimulation of cytotoxic or killer cells, which may recognise and destroy (or otherwise eliminate) cells expressing "foreign" antigens on their surface. The term "stimulating an immune response" thus includes all types of immune responses and mechanisms for stimulating them.

The stimulation of cytotoxic cells or antibody-producing cells, requires antigens to be presented to the cell to be stimulated in a particular manner by the antigen-presenting cells, for example MHC Class I presentation (e.g. activation of CD8⁺ cytotoxic T-cells requires MHC-1 antigen presentation).

Antigen-presenting cells are known in the art and described in the literature and include for example, lymphocytes (both T and B cells), dendritic cells, macrophages etc. Others include for example cancer cells e.g. melanoma cells.

For antigen presentation by an antigen-presenting cell to a cytotoxic T-cell (CTL) the antigenic molecule needs to enter the cytosol of the antigen-presenting cell (Germain, cell, 1994, 76, 287-299). The present invention provides an efficient means of delivery of the antigenic molecule into the cytosol.

Once released in the cell cytosol by the photochemical internalisation process, the antigenic molecule may be processed by the antigen-processing

machinery of the cell and presented on the cell surface in an appropriate manner e.g. by Class I MHC. This processing may involve degradation of the antigen, e.g. degradation of a protein or polypeptide antigen into peptides, which peptides are then complexed with molecules of the MHC for presentation. Thus, the antigenic molecule expressed or presented on the surface of the cell according to the present invention may be a part or fragment of the antigenic molecule which is internalised (endocytosed).

Antigens may be taken up by antigen-presenting cells by endocytosis and degraded in the endocytic vesicles to peptides. These peptides may bind to MHC class II molecules in the endosomes and transported to the cell surface where the peptide-MHC class II complex may be recognised by CD4+ T helper cells and induce an immune response. Alternatively, proteins in the cytosol may be degraded, e.g. by proteasomes and transported into endoplasmic reticulum by means of TAP (transporter associated with antigen presentation) where the peptides may bind to MHC class I molecules and transported to the cell surface as illustrated in the figure (Yewdell and Bennink, 1992, Adv. Immunol. 52: 1-123). If the peptide is of foreign, antigen origin, the peptide-MHC class I complex will be recognised by CD8+ cytotoxic T-cells (CTLs). The CTLs will bind to the peptide-MHC (HLA) class I complex and thereby be activated, start to proliferate and form a clone of CTLs. The target cell and other target cells with the same peptide-MHC class I complex on the cells surface may be killed by the CTL clone. Immunity against the foreign antigen may be established if a sufficient amount of the antigen can be introduced into the cytosol (Yewdell and Bennink, 1992, supra; Rock, 1996, Immunology Today 17: 131-137). This is the basis for development of *inter alia* cancer vaccines. One of the largest practical problems is to introduce sufficient amounts of antigens (or parts of

the antigen) into the cytosol. This may be solved according to the present invention by PCI. This principle is illustrated in Fig. 1, which shows how PCI can be utilised to stimulate CTLs. A peptide or protein (P) is applied extracellularly to antigen-presenting cells. P is endocytosed and released into cytosol by PCI. The peptide or protein will thereafter be partly degraded by proteasomes and transported to the cells surface complexed to MHC (HLA) class I where the complex can be recognised by CTLs.

As will be described in more detail in the Examples below, it has been demonstrated that photochemical internalisation may be used efficiently according to the present invention for cytosolic delivery of cancer-specific peptides.

The antigenic molecule and/or photosensitivity agent may be targeted to specific cells or tissues by employing targeting agents e.g. target-specific delivery or carrier systems or carrier molecules. Thus for example the antigenic molecule and/or photosensitising agent may be delivered to the cell using a vector or carrier system e.g. reconstituted LDL-particles. The carrier molecule may be bound or conjugated to the antigenic molecule, to the photosensitising agent or both, and the same or different carrier molecules may be used. The antigenic molecule and/or photosensitising agent may also be conjugated to a site-targeting ligand, such as a ligand which is specific for particular cell-types or particular cell structures e.g. an antibody recognising a surface antigen expressed on certain cell types e.g. a tumour-specific antigen. Such mechanisms may act to increase uptake of the photosensitiser and/or antigen molecule through receptor-mediated endocytosis. Such targeting molecules carriers or vectors may also be used to direct the antigenic molecule and/or photosensitising agent to the intracellular compartment.

The intracellular membrane-restricted compartment

may be any such compartment which is present in a cell. Preferably the compartment will be a membrane vesicle, especially an endosome or a lysosome. However, the intracellular compartment may also include the Golgi apparatus or the endoplasmic reticulum. All that is required is that the antigenic molecule and the photosensitising agent locate to the same intracellular compartment(s).

The photochemical internalisation process is described in more detail in WO 96/07432 (the contents of which are incorporated herein by reference). Methods of PDT are also now widely described in the literature.

The photosensitizing agent to be used according to the present invention may be any such agent which localises to intracellular compartments, particularly endosomes or lysosomes. A range of such photosensitising agents are known in the art and are described in the literature, including in WO96/07432. Mention may be made in this respect of di- and tetrasulfonated aluminium phthalocyanine, sulfonated tetraphenylporphines (TPPS_n), nile blue, chlorin e₆ derivatives, uroporphyrin I, phylloerythrin, hematoporphyrin and methylene blue which have been shown to locate in endosomes and lysosomes of cells in culture. This is in most cases due to endocytic activity.

Classes of suitable photosensitising agent which may be mentioned thus include porphyrins, phthalocyanines, purpurins, chlorins, benzoporphyrins naphthalocyanines, cationic dyes, tetracyclines and lysomotropic weak bases or derivatives thereof (Berg et al., J. Photochemistry and Photobiology, 1997, 65, 403-409).

Preferred photosensitising agents include TPPS₄ (Zabner et al., J. Biol. Chem. 1995, 270, 18997-19007) TPPS_{2a} and AlPcS_{2a}.

The photochemical internalisation according to the

present invention may be carried out using PDT methods which are known and standard in the art. Thus, the antigenic molecule and photosensitising agent may be delivered to the cell by application or administration according to methods and means known in the art of PDT.

The methods of the present invention may be used *in vitro* or *in vivo*, either by *in situ* treatment or by *ex vivo* treatment, followed by administration of the treated cells.

Thus, a further aspect of the invention provides an antigen-presenting cell expressing an antigenic molecule, or a part thereof, on its surface, which cell is obtainable (or obtained) by a method as hereinbefore defined. Other aspects of the invention provide a population or culture of such cells, especially a viable and functionally intact population or culture of such cells, and also the use of such a cell (or population or culture of cells) in therapy, particularly for stimulating an immune response, and especially for stimulating CTLs.

Also provided is the use of such a cell (or population or culture of cells) for the preparation of a composition (e.g. a vaccine composition) for stimulating an immune response, and especially for stimulating CTLs.

In vivo, any mode of administration common or standard in the art may be used, e.g. injection, infusion, topical administration, both to internal and external body surfaces etc. For *in vivo* use, the invention can be used in relation to any tissue which contains the target cells, including body fluid locations, as well as solid tissues. All tissues can be treated as long as the photosensitiser is taken up by the target cells, and the light can be properly delivered.

Thus, the compositions of the invention may be formulated in any convenient manner according to techniques and procedures known in the pharmaceutical

art, e.g. using one or more pharmaceutically acceptable carrier or excipients. The nature of the composition and carriers or excipient materials, dosages etc. may be selected in routine manner according to choice and the
5 desired route of administration, purpose of vaccination etc. Dosages may likewise be determined in routine manner and may depend upon the nature of the antigenic molecule, purpose of vaccination, age of patient, mode of administration etc., in connection with the
10 photosensitising agent the potency/ability to disrupt membranes on irradiation, should also be taken into account.

The light irradiation step to activate the photosensitising agent may likewise take place according
15 to techniques and procedures well known in the art. For example, the wavelength and intensity of the light may be selected according to the photosensitising agent used. Suitable light sources are well known in the art.

As mentioned earlier, and as described in
20 WO96/07432, it has been found that photochemical internalisation in this manner does not deleteriously affect the viability and functionality of the cells. In particular, it has been found that when a population or plurality of cells is treated according to the present
25 invention, a majority of the cells is not killed, and survives the treatment, substantially functionally intact.

As used herein, the term "without killing the cell" is intended to define such a situation. In other words
30 in a population or plurality of cells, substantially all of the cells, or a significant majority (e.g. at least 75%, more preferably at least 80, 85, 90 or 95% of the cells) are not killed.

The methods of the invention may be modified such
35 that the fraction or proportion of the surviving cells is regulated by selecting the light dose in relation to the concentration of the photosensitising agent. Again,

such techniques are known in the art.

The present invention provides an efficient means for delivery of a large variety of antigenic molecules. The invention has a number of features rendering it particularly suitable as a vaccine delivery tool: 1) it has no restrictions on the size of the molecule to be delivered as long as the molecule can be endocytosed by the target cell; 2) it is not dependent on cell proliferation; 3) it is site specific in that only areas exposed to light are affected; 4) it is not oncogenic. In addition, photochemical internalisation may potentially be combined with other principles for generating site or tissue specific drug action, such as targeting by the use of specific ligands for cell surface structures, employing regulatory gene elements that confer tissue specificity or the use of disease-specific drugs, opening a possibility of obtaining substantially synergistic effects in the specificity of drugs for target cells.

The invention will now be described in more detail in the following non-limiting Examples with reference to the following drawings in which:

Figure 1 shows a schematic representation of how PCI can be utilised to stimulate CTLs. A peptide or protein (P) is applied extracellularly to antigen-presenting cells. P is endocytosed and released into cytosol by PCI. The peptide or protein will thereafter be partly degraded by proteasomes and transported to the cells surface complexed to MHC (HLA) class I where the complex can be recognised by CTLs.

Figure 2 shows photochemically induced relocation of a peptide. BL2-G-E6 cells were incubated with a fluorescein-labelled p21^{ras}-derived 5-21, Val¹² peptide and AlPcS_{2a}. The cells were examined for fluorescein-peptide and AlPcS_{2a} localisation by fluorescence microscopy before (top panels) and 30 minutes after (bottom panels) a 4-min exposure to red

light. Bar 20 μ m.

Figure 3 shows the cytotoxicity of a CD8⁺ T lymphocyte clone against FM3 melanoma cells after PCI of a MART-1 peptide.

5 Figure 4 shows the ability of PCI to deliver HRP into the cytosol. NHIK 3025 cells were treated with 3.2 μ g/ml TPPS_{2a} and 1 mg/ml HRP for 18 hours. The medium was then replaced with drug-free medium before exposure to the indicated light doses. HRP activity was measured
10 in intact cells (○) and in cytosol (●) separated from cytosol-free cell corpses (▼) by electropermeabilisation and a density centrifugation technique.

Figure 5 shows photochemically induced expression of GFP. a. expression of GFP in THX cells treated with
15 pEGFP-N1-pLys complex in the absence of AlPcS_{2a} and light or in the presence of AlPcS_{2a} followed by exposure to light as indicated on the figure. The cells were analysed by flow cytometry, reckoning the cells on the right side of the drawn line as positive for GFP
20 expression. b. expression of GFP in THX cells treated for 18 hours with a photosensitiser (20 μ g/ml AlPcS_{2a} or 0.25 μ g/ml 3-THPP) followed by a 6 hour transfection with pEGF-N1-pLys complex and exposure to light inactivating 50% of the cells. GFP expression was
25 analysed by flow cytometry as described in a.

EXAMPLES

Materials and Methods

5 Irradiation

Two different light sources were used for treatment of the cells, both consisting of a bank of 4 fluorescent tubes. Cells treated with TPPS₄, TPPS_{2a}, and 3-THPP (Porphyrin Products, Logan, UT) were exposed to blue light (model 3026; Appl. Photophysics, London, UK) with a light intensity reaching the cells of 1.5 mW/cm² while cells treated with AlPcS_{2a} (Porphyrin Products, Logan, UT) were exposed to red light (Philips TL 20W/09) filtered through a Cinemoid 35 filter with a light intensity reaching the cells of 1.35 mW/cm².

Fluorescence microscopy

20 The cells were analysed by fluorescence microscopy as described in Berg. K., et al., Biochem. Biophys. Acta., 1370: 317-324, 1998. For analysis of fluorescein-labelled molecules the microscope was equipped with a 450-490 nm excitation filter, a 510 nm dichroic beam splitter and a 510-540 nm band pass emission filter.

Preparation of Plasmid-pLys Complexes and Treatment of cells

30 Plasmid-pLys complexes (charge ratio, 1.7) were prepared by gently mixing 5 µg plasmid (pEGFP-N1; Clontech Laboratories, Inc., Palo Alto, CA) in 75 µl of HBS with 5.3 µg pLys (MW 20700; Sigma, St. Louis, MO) in 75 µl of HBS. The solutions were incubated for 30 min at room temperature, diluted with culture medium and added to the cells.

THX cells were incubated with 20 $\mu\text{g/ml}$ AlPcS_{2a} for 18 hours at 37°C, washed and incubated in sensitizer-free medium for 3 hours before incubation with plasmid-pLys complexes for 2 hours. The pEGFP-N1/pLys treated THX
5 cells were washed once and incubated for 2 hours in culture medium without additions before exposure to light. The cells were incubated at 37°C for 2 days, subcultured and further incubated for an additional 5 days before analysis of GFP expression by flow
10 cytometry.

HCT-116 cells were incubated with 20 $\mu\text{g/ml}$ AlPcS_{2a} for 18 hours, washed and transfected with plasmid-pLys complexes for 6 hours before light exposure in plasmid-free medium. After 40 hours incubation at 37°C the GFP
15 expression was studied by microscopy.

Flow cytometry analysis

20 The cells were trypsinised, centrifuged, resuspended in 400 μl of culture medium and filtered through a 50 μm mesh nylon filter. The cells were then analysed in a FACStar plus flow cytometer (Becton Dickinson). Green Fluorescent Protein (GFP) was measured through a 510-530
25 nm filter after excitation with an argon laser (200 mW) tuned on 488 nm. AlPcS_{2a} was measured through a 650 nm longpass filter after excitation with a krypton laser (50 mW) tuned on 351-356 nm. Cell doublets were discriminated from single cells by gating on the pulse
30 width of the GFP fluorescence signal. The data were analysed with PC Lysys II software (Becton Dickinson).

Preparation of Fluorescein-Peptide and Treatment of Cells

35

The fluorescein-labelled Val^{12} -p21^{ras}-peptide (residues 5-21) were synthesised and provided by Alan Cuthbertson,

Nycomed Amersham).

BL2-G-E6 cells were incubated with 30 $\mu\text{g/ml}$ of the
fluorescein-labelled p21^{ras}-derived peptide for 18 hours
5 followed by 20 $\mu\text{g/ml}$ AlPcS_{2a} for 18 hours and 1 hour in
drug-free medium before exposure to red light.

Example 1

10 Photochemical internalisation (PCI) can be used to
enable peptides to enter the cytosol of cells

To evaluate PCI for cytosolic delivery of cancer-
specific peptides, a fluorescein-labelled p21^{ras} peptide
15 encompassing residues 5-21 and containing a Val¹²
mutation (G12V) was used (Gjertsen, M.K., et al., Int.
J. Cancer, 72: 784-790, 1997). In BL2-6-E6 mouse
fibroblasts, the ras peptide colocalised well with
AlPcS_{2a}, indicating endocytic uptake of the peptide (Fig.
20 2). After a 4-min exposure to light, the fluorescein-
labelled ras peptide and AlPcS_{2a} were found to be located
diffusely in the cytoplasm. Similar effects were not
observed in cells exposed to the fluorescein-labelled
ras peptide and light only (data not shown).

25

Example 2

Use of PCI to induce antigen presentation and CD8⁺ T lymphocyte mediated cell killing

5

FM3 melanoma cells (2×10^5 /well in 6 well plates), grown in RPMI 1640 medium with 10% foetal calf serum (FCS), not expressing MART-1 peptide were treated with 10 μ g/ml of the photosensitising agent AlPcS_{2a} for 18 hours. The cells were then released from the substratum with EDTA (0.1 M) in Dulbecco's phosphate-buffered saline (PBS) and kept in solution during loading of the cells with ⁵¹Cr (60 μ Ci/ml Na₂CrO₄) for 1 hour in 100% FCS followed by 5 hours incubation with 5 μ g/ml MART-1 peptide in RPMI 1640 in 10% FCS, while the cells were still kept in solution. The sequence of the MART-1 peptide was: TAEAAAGIGILTVILG. The cells were then washed twice in RPMI 1640 medium containing 10% FCS and seeded out in 96-well plates (2000/well in 100 μ l medium (RPMI 1640/10% FCS). The cells were then exposed to light for the times as indicated in Figure 3 ((Philips TL 20W/09) filtered through a Cinemoid 35 filter with a light intensity reaching the cells of 1.35 mW/cm² (Rodal et al., 1998, J. Photochem. Photobiol. B: Biol. 45: 150-9)). 18 hours after light exposure the medium was removed and medium containing MART-1/HLA-A2 specific cytotoxic T lymphocytes (CTLs - 40,000/well added in 100 μ l) were added. After 4 hours of incubation the medium was separated from FM3 cells and the ⁵¹Cr released to the medium (as an indicator of lysed cells) was counted as well as the spontaneous and maximum release as previously described (Fossum et al., 1995, Cancer Immunol. Immunother. 40: 165-172). The percentage specific chromium release was calculated by the formula: (experimental release - spontaneous release)/(maximum release - spontaneous release) x 100. It can be seen from the results shown in Figure 3 that FM3 cells after

PCI of a MART-1 peptide as outlined above show light dependent susceptibility to CD8⁺ T lymphocyte cytotoxicity.

5 Example 3

PCI induces the release of a large fraction of the endocytosed molecule

10 This was shown by PCI induced internalisation/ endocytosis of Horseradish Peroxidase (HRP).

By using HRP, it is demonstrated (see Figure 4) that PCI induces the release of a large fraction (>60%) of
15 endocytosed HRP into the cytosol.

In this experiment NHIK 3025 cells (carcinoma cells in situ from human cervix) were treated with the photosensitising agent TPPS_{2a} (3.2 µg/ml) and 1 mg/ml HRP
20 for 18 hours. The medium was then replaced with drug free medium before exposure to the light doses as indicated in Figure 4. HRP activity was measured according to the procedure described in Steinman et al., J. Cell Biol., 68: 665-687, 1976. Cytosol was separated
25 from cytosol-free cell corpses by electroporabilisation and a density centrifugation technique (Berg et al., Int. J. Cancer 59: 814-822, 1994).

30 Example 4

PCI can be used to enhance the delivery of functional genes

35 To demonstrate this, THX cells were transfected with a pLys-complex of a plasmid (pEGFP-N1) coding for green fluorescent protein (GFP). The expression of GFP was

analysed by flow cytometry (Fig. 5, a and b) and fluorescence microscopy (data not shown). As can be seen from Fig. 5a, treatment with AlPcS_{2a} and light led to a strong increase in the percentage of the cells expressing GFP. The fraction of the cells that was positive for this reporter molecule increased from 1% at no light treatment to 50% after a 5-min light exposure. GFP expression was not enhanced by light in cells treated with pEGFP-pLys in the absence of a photosensitiser. A complex of an irrelevant plasmid (encoding heme oxygenase) and pLys did not induce green fluorescence when combined with AlPcS_{2a} and light (data not shown). Consequently, in a light-directed manner, PCI can substantially increase the efficiency of transfection of a functional gene to THX cells. Similar results were obtained using TPPS_{2a} as a photosensitiser and BHK-21 and HCT-116 as target cells (data not shown). The essentially non-lysosomally located sensitiser 3-THPP induced only a minor increase in GFP expression (Fig. 5b). PCI of pEGFP-N1 not complexed with pLys did not induce the expression of GFP (data not shown).





FIGURE 1



2/5





FIGURE 2



3/5





FIGURE 3







FIGURE 4







FIGURE 5

